News|Articles|November 18, 2026

Type 2 diabetes associated with 53% higher Alzheimer’s risk, with claims data likely undercounting cases, review shows

Author(s)Logan Lutton
Listen
0:00 / 0:00

A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.

Adults with type 2 diabetes carried a 53% higher risk of Alzheimer’s disease and approximately five of every 1,000 developed the disease for each year they were followed, according to a meta-analysis published recently in Alzheimer’s Research and Therapy.

The analysis was led by Emmanuel Adewuyi, Ph.D., NHMRC Investigator Fellow in the Curtin School of Population Health in Australia. He and his team’s analysis included 40 studies from 12 countries, accounting for more than 27,102,559 data points. Most were large cohorts from Korea, the United States and the United Kingdom.

The elevated risk held up across several alternate analyses and was similar for men and women, though women showed somewhat higher incidence. The authors stressed that the finding reflects an association across populations rather than evidence that diabetes causes Alzheimer’s, noting that metabolic and vascular factors, lifestyle, medications and unmeasured confounders may all contribute.

Why claims data may undercount Alzheimer’s in diabetes

How Alzheimer’s was identified made a large difference. Studies that relied on billing codes and other administrative records found approximately four cases per 1,000 person-years, while those using non-administrative diagnostic criteria found approximately 10 cases per 1,000 person-years. The authors suggested coding-based approaches likely miss milder cases that structured clinical assessments would pick up. Incidence was highest in North America (7.54 per 1,000) and lowest in Europe and Central Asia (1.17 per 1,000), a difference the authors said could reflect regional variation in cardiometabolic risk, access to care or case-finding, though they noted those explanations have not been tested directly.

“While many earlier reviews combined different types of diabetes or dementia, this review focused specifically on type 2 diabetes and Alzheimer’s disease and estimated how often new cases occurred,” Adewuyi said in a news release. “Relative risk tells us how two groups compare, while incidence tells us how often new cases occur: putting those numbers together gives us a clearer picture of the burden of Alzheimer’s disease among people living with type 2 diabetes.”

For health plans, the two conditions tend to concentrate in the same aging, high-cost members. Diabetes affects an estimated 12% of the U.S. population, including approximately 11 million adults who have not been diagnosed, according to the CDC. More than 7 million Americans are living with Alzheimer’s, and the cost of caring for people with Alzheimer’s and other dementias is estimated to total $409 billion this year, according to the Alzheimer’s Association.

Where GLP-1s and other diabetes drugs fit

Differences in which glucose-lowering drugs patients took may explain part of the variation across studies, according to the researchers. They pointed to prior work associating metformin, pioglitazone and acarbose with lower dementia risk, along with observational and network meta-analysis evidence suggesting GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors may also be tied to lower dementia risk in type 2 diabetes.

That evidence remains observational, but the authors said their estimates could serve as a reference point for future studies designed to test whether treating metabolic disease changes a patient’s odds of developing Alzheimer’s.

The researchers argued that the incidence figure, more than the relative risk, is the number health systems can put to work.

“While relative risks are valuable for etiological inference, incidence rates provide a direct measure of disease burden that is highly relevant for risk stratification, prevention planning and health-system forecasting,” Adewuyi and his team wrote in the study.


Related to this article